Poly Medicure Limited has delivered robust performance for Q4 and FY26, with consolidated revenue reaching Rs 1,875.3 crore, representing a 12.3% YoY growth. The company achieved a record standalone quarterly revenue in Q4 FY26. Strategic acquisitions, including PendraCare and Citieffe, alongside consistent innovation, continue to drive long-term value, despite temporary margin impacts from consolidation costs. The company maintains a strong liquidity position of Rs 842.2 crore as of March 31, 2026.
Financial Performance Highlights
Poly Medicure reported a resilient financial year ending March 31, 2026. On a standalone basis, the company achieved revenue of Rs 1,662.5 crore, a 3.8% increase, while consolidated revenue grew by 12.3% to Rs 1,875.3 crore. Despite integration costs related to acquisitions, the company sustained a healthy consolidated operating EBITDA of Rs 457.7 crore with a margin of 24.4%.
Strategic Acquisitions and Segment Growth
The current fiscal year was marked by the successful consolidation of PendraCare Group and Citieffe Group, which are pivotal to the company’s roadmap in high-end technology segments like cardiology and orthopaedics. The Renal and Others segments showed strong momentum, recording 24.5% and 36.3% growth respectively for the full year. These segments now represent a significant portion of the company’s diversified portfolio mix.
Innovation and Global Footprint
Innovation remains the core driver for Poly Medicure, supported by a dedicated R&D team of 90 professionals across India, Italy, and the Netherlands. The company launched 35 new products in FY26 and now holds over 390 patents. With 15 manufacturing plants across 5 countries, the company continues to solidify its position as a global leader in medical consumables, serving over 125 countries through a vast network of 1,000+ distributors.
Future Outlook
Looking ahead, the company is focused on scaling its manufacturing capacity, particularly with two upcoming plants in India. Strategic priorities include increasing R&D investments, pursuing inorganic growth, and expanding into the US market. The company remains committed to sustainability, with approximately 70% of its facilities certified under ISO 14001:2015 and an active focus on reducing Scope 2 emissions through increased utilization of solar power.
Source: BSE
